Molekulyarno-geneticheskaya geterogennost' melanomy kozhi i ee znachenie dlya razrabotki individual'nykh podkhodov k lecheniyu


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Metastatic skin melanoma is characterized by a poor prognosis of the disease. Chemotherapy for metastatic and unresectable skin melanoma is still a challenge. Efficiency of one-component regimens (monochemotherapy) does not exceed 10-15 %. Unfortunately, some improvement in progression-free survival observed during polychemotherapy has no effect on overall survival of patients. A promising direction of increasing the effectiveness of therapy and overall survival of patients with metastatic melanoma includes the individualization of drug treatment, with the determination of the molecular-genetic changes in the tumor and the treatment based on these results. This article reviews current treatment options with new promising targeted drugs.

Full Text

Restricted Access

References

  1. Sosman J. Educational book, ASCO. 2011. P. 367-72.
  2. Jacquillat C, et al. Final Report of the French Multicenter Phase II Study of the Nitrosourea Fotemustine in 153 Evaluable Patients With Disseminated Malignant Melanoma Including Patients With Cerebral Metastases. Cancer. 1990;66:1873-78.
  3. Chapman P.B., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Clin. Oncol. 1999;17:2745-51.
  4. Middleton M.R., et al. Randomized phase III study of temozolomide versus dacarbazine in the Treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000;18(1):158-66.
  5. Atkins M.B., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2008;26:5748-54.
  6. Coit D.G., Thompson J.A., Andtbacka R. et al. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. Melanoma 2014;2.
  7. Демидов Л.В. и др. Практические рекомендации общества онкологов-химиотерапевтов по диагностике, лечению и наблюдению больных меланомой кожи. Версия 2012 г.
  8. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
  9. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851-57.
  10. Демидов Л.В., Орлова К.В. Индивидуализация лекарственного лечения меланомы кожи. Практическая онкология. 2013;14(4): 239-46.
  11. McArthur G, Chapman P., Robert C., et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. Lancet Oncology. 2014;15:232-32.
  12. Инструкция по медицинскому применению препарата, ЛП-002271.
  13. Hauschild A., Grob J.J., Demidov L.V., et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. Annual Meeting Abstracts. J. Clin. Oncol. 2012;30(18_suppl):abstr LBA8500.
  14. Robert C., Flaherty K.T., Hersey P., et al. METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). ASCO Annual Meeting Abstracts. J. Clin. Oncol. 2012;30(15suppl): LBA8509.
  15. U.S. Food and Drug Administration. Approved Drugs. 2014.
  16. Ribas A., et al. BRIM7-Vemurafenib + cobimetinib Phase 1B study in BRAF mutant melanoma. Oral presentation to be presented at 10th European Association of Dermato-Oncology (EADO); Vilnius, Lithuania; 7-10 May 2014.
  17. McArthur G., Ascierto P., Larkin J., et al. Phase 3, double-Blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in pre viously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). ESMO. 2014;Abstract LBA5_PR.
  18. Larkin J., Ascierto P.A., Dreno B., et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. NEJM. 2014. doi: 10.1056/NEJ Moa 1408868
  19. Демидов Л.В., Утяшев И.А., Харкевич Г.Ю. Подходы к диагностике и терапии меланомы кожи эра персонализированной медицины. Consilium medicum. Дерматология. 2013;2:42-47.
  20. NCCN Guidelines Version 4.2014. Melanoma.
  21. Guo J., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 2011 ;29(21):2904-09. doi: 10.1200/Jœ.201033.9275. Epub2011 Jun 20.
  22. Sosman J.A., et al. ASCO. 2014; Abstract 9009.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies